-
-
[1]Browning J, Szczepaniak L, Dobbins R, et al.Prevalence of hepaticsteatosis in an urban population in the United States:impact of eth-nicity[J].Hpatology, 2004, 40∶1387-1395. [2]Choudhury J, Sanyal AJ.Insulin resistance and the pathogenesis ofnonalcoholic fatty liver disease[J].Clin Liver Dis, 2004, 8 (3) ∶575-594. [3]Hui JM, Hodge A, Fatrrell GC, et al.Beyond insulin resistance inNASH:TNF-alpha or adiponectin?[J].Hepatology, 2004, 40 (1) ∶46-54. [4]Jepsen P, Vilstrup H, Mellemkjaer L, et al.Prognosis of patientswith a diagnosis of fatty liver-a registry-based corhort study[J].Hepatogastroenterolohy, 2003, 50∶2101-2104. [5]Dam-Larsen S, Franzmann M, Andersen IB, et al.Long termprognosis of fatty liver:risk of chronic liver disease and death[J].Gut, 2004, 53∶750-755. [6]Matteoni CA, Younossi ZM, Gramlich T, et al.Nonalcoholic fattyliver disease:a spectrum of clinical and pathological sererity[J].Gastroenterology, 1999, 116∶1413-1419. [7]Adams LA, Sanderson S, Lindor KD, et al.The histological courseof nonalcoholic fatty liver disease:a longitudinal of103 patients withsequential liver biopsies[J].J Hepatol, 2005, 42 (1) ∶132-138. [8]American Gastroentrological Association.Nonalcoholic fatty liver dis-ease[J].Gastroenterology, 2002, 123∶1702-1704. [9]中华医学会.非酒精性脂肪性肝病诊断标准[J].中华肝脏病杂志, 2003, 11 (2) ∶71. [10]Promrat K, Lutchman G, Uwaifo GI, et al.Apilot study of pioglita-zone trealment for nonalcoholic steatohepatitis[J].Hepatology, 2004, 39 (1) ∶188-196. [11]Portincasa P, Grattagliano 1, Palmieri VO, et al.Nonalcoholicsteatohepatitis:recent advances form experimental models to clinicalmanagement[J].clin Biochem, 2005, 38∶203-217. [12]Bugianesi E, Gentilcore E, Manini R, et al.A randomized con-trolled trial of menformin versus vitamin E or prescriptive diet in non-alcoholic fatty livder disease[J].Am J Gastroentero, 2005, 100∶1082-1090. [13]Nair S, Diehl AM, Wiseman M, et al.Metformin in the treatmentof nonalcoholic steatohepatitis:a pilot label trial[J].Aliment Pharma-col Ther, 2004, 20 (1) ∶23-28. [14]Adams LA, Zein CO, Angulo P, et al.A Pilot trial of pentoxifyl-line in nonalcoholic steatohepatis[J].Am J Gastroterol, 2004, 99∶2365-2368. [15]Merat S.Malekzadeh R, Sohabi MR, et al.Probucol in the treat-ment of nonalcoholic steatohepatitis a double-blind randomized con-trolled study[J].Hepatol.2003, 38∶414-146. [16]Yokohama S, Yoneda M, Okamoto S, et al.Therapeutic efficacy ofan angiotensinⅡrecepor antagonist in patients with nonalcoholicsteatohepatitis[J].Hepatology, 2004, 40∶1222-1225.
本文二维码
计量
- 文章访问数: 3034
- HTML全文浏览量: 10
- PDF下载量: 832
- 被引次数: 0